These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37933625)

  • 1. Obstructive hypertrophic cardiomyopathy: a review of new therapies.
    Mehra N; Ali AH; Desai MY
    Future Cardiol; 2023 Oct; 19(13):661-670. PubMed ID: 37933625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy and the impact of mavacamten.
    Mathai S; Williams L
    Ther Adv Chronic Dis; 2022; 13():20406223221136074. PubMed ID: 36407022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults.
    Dong T; Nissen S; Ospina S; Desai MY
    Expert Rev Cardiovasc Ther; 2023 Jan; 21(1):5-13. PubMed ID: 36522857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-modality management of hypertrophic cardiomyopathy.
    Rao SJ; Iqbal SB; Kanwal AS; Aronow WS; Naidu SS
    Hosp Pract (1995); 2023 Feb; 51(1):2-11. PubMed ID: 36598161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions.
    Dong T; Alencherry B; Ospina S; Desai MY
    Drug Des Devel Ther; 2023; 17():1097-1106. PubMed ID: 37064432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D;
    Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invasive therapies for symptomatic obstructive hypertrophic cardiomyopathy.
    Mehra N; Veselka J; Smedira N; Desai MY
    Prog Cardiovasc Dis; 2023; 80():46-52. PubMed ID: 37652213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
    Sebastian SA; Padda I; Lehr EJ; Johal G
    Am J Cardiovasc Drugs; 2023 Sep; 23(5):519-532. PubMed ID: 37526885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy.
    Zampieri M; Argirò A; Marchi A; Berteotti M; Targetti M; Fornaro A; Tomberli A; Stefàno P; Marchionni N; Olivotto I
    Curr Cardiol Rep; 2021 Jun; 23(7):79. PubMed ID: 34081217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving Strategies for the Management of Obstructive Hypertrophic Cardiomyopathy.
    Liang LW; Lumish HS; Sewanan LR; Shimada YJ; Maurer MS; Weiner SD; Clerkin KJ
    J Card Fail; 2024 May; ():. PubMed ID: 38777216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertrophic cardiomyopathy: investigational drugs inhibiting myosin and upcoming agents.
    Hajj Ali A; Mehra N; Desai MY
    Expert Opin Investig Drugs; 2023; 32(9):849-853. PubMed ID: 37787068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy.
    Ho CY; Olivotto I; Jacoby D; Lester SJ; Roe M; Wang A; Waldman CB; Zhang D; Sehnert AJ; Heitner SB
    Circ Heart Fail; 2020 Jun; 13(6):e006853. PubMed ID: 32498620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary Therapies and Future Directions in the Management of Hypertrophic Cardiomyopathy.
    Packard E; de Feria A; Peshin S; Reza N; Owens AT
    Cardiol Ther; 2022 Dec; 11(4):491-507. PubMed ID: 36243823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study.
    Cremer PC; Geske JB; Owens A; Jaber WA; Harb SC; Saberi S; Wang A; Sherrid M; Naidu SS; Schaff H; Smedira NG; Wang Q; Wolski K; Lampl KL; Sehnert AJ; Nissen SE; Desai MY
    Circ Cardiovasc Imaging; 2022 Dec; 15(12):e014986. PubMed ID: 36335645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy.
    Chase Cole J; Benvie SF; DeLosSantos M
    Clin Ther; 2024 Apr; 46(4):368-373. PubMed ID: 38508915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy.
    Reyes KRL; Bilgili G; Rader F
    Heart Int; 2022; 16(2):91-98. PubMed ID: 36741099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aficamten-A Second in Class Cardiac Myosin Inhibitor for Hypertrophic Cardiomyopathy.
    Patel J; Wang A; Naidu SS; Frishman WH; Aronow WS
    Cardiol Rev; 2023 Oct; ():. PubMed ID: 37881953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of the Submitral Apparatus in Hypertrophic Obstructive Cardiomyopathy.
    Tao J; Duan F; Long J; Meng Q; Zhang B; Zhu Z; Wang H
    J Am Soc Echocardiogr; 2023 Feb; 36(2):133-145. PubMed ID: 36191671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mavacamten-A Targeted Therapy for Hypertrophic Cardiomyopathy.
    Schenk A; Fields N
    J Cardiovasc Pharmacol; 2023 May; 81(5):317-326. PubMed ID: 36878205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and emerging pharmacotherapy for the management of hypertrophic cardiomyopathy.
    Rosenzveig A; Garg N; Rao SJ; Kanwal AK; Kanwal A; Aronow WS; Martinez MW
    Expert Opin Pharmacother; 2023; 24(12):1349-1360. PubMed ID: 37272195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.